Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) on Monday, soared 4.91% from the previous trading day, before settling in for the closing price of $0.24. Within the past 52 weeks, ADAP’s price has moved between $0.20 and $1.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 175.28%. The company achieved an average annual earnings per share of -74.52%. With a float of $228.63 million, this company’s outstanding shares have now reached $257.85 million.
Let’s determine the extent of company efficiency that accounts for 506 employees. In terms of profitability, gross margin is 98.06%, operating margin of -36.31%, and the pretax margin is -38.17%.
Adaptimmune Therapeutics Plc ADR (ADAP) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.33%, while institutional ownership is 34.07%. The most recent insider transaction that took place on Jan 17 ’25, was worth 3,243. In this transaction Chief Medical Officer of this company sold 5,584 shares at a rate of $0.58, taking the stock ownership to the 7,510 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Patient Supply Officer sold 5,584 for $0.58, making the entire transaction worth $3,243. This insider now owns 7,510 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -74.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -28.83% during the next five years compared to 26.53% growth over the previous five years of trading.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Adaptimmune Therapeutics Plc ADR (ADAP) is currently performing well based on its current performance indicators. A quick ratio of 1.79 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.27, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.14 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Looking closely at Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP), its last 5-days average volume was 0.85 million, which is a drop from its year-to-date volume of 1.49 million. As of the previous 9 days, the stock’s Stochastic %D was 16.77%. Additionally, its Average True Range was 0.02.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 13.86%, which indicates a significant decrease from 20.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.35% in the past 14 days, which was lower than the 117.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2686, while its 200-day Moving Average is $0.5833. However, in the short run, Adaptimmune Therapeutics Plc ADR’s stock first resistance to watch stands at $0.2641. Second resistance stands at $0.2741. The third major resistance level sits at $0.2849. If the price goes on to break the first support level at $0.2433, it is likely to go to the next support level at $0.2325. Now, if the price goes above the second support level, the third support stands at $0.2225.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
Market capitalization of the company is 65.55 million based on 265,052K outstanding shares. Right now, sales total 178,030 K and income totals -70,810 K. The company made 7,290 K in profit during its latest quarter, and -47,580 K in sales during its previous quarter.
